![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sofosbuvir/Velpatasvir (S/V) for the treatment
of HCV infection among vulnerable inner-city residents:
extending the results of clinical trial
|
|
|
EASL 2022 June 22-26 London
Brian Conway1,2, David Truong1, Leo Yamamoto1, Rossitta Yung1, Shawn Sharma1. 1Vancouver Infectious Diseases Centre, Vancouver, Canada; 2Simon Fraser University, Burnaby, Canada
![0622221](../images/062222/062222-8/0622221.gif)
![0622222](../images/062222/062222-8/0622222.gif)
![0622223](../images/062222/062222-8/0622223.gif)
![0622224](../images/062222/062222-8/0622224.gif)
![0622225](../images/062222/062222-8/0622225.gif)
![0622226](../images/062222/062222-8/0622226.gif)
![0622227](../images/062222/062222-8/0622227.gif)
![0622228](../images/062222/062222-8/0622228.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|